Blueprint Medicines [BPMC] vs Vertex [VRTX] Detailed Stock Comparison
Blueprint Medicines
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Blueprint Medicines wins in 6 metrics, Vertex wins in 12 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Blueprint Medicines | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -120.99 | 28.68 | Blueprint Medicines |
| Price-to-Book Ratio | 24.43 | 6.02 | Vertex |
| Debt-to-Equity Ratio | 208.50 | 8.89 | Vertex |
| PEG Ratio | -137.72 | -0.22 | Blueprint Medicines |
| EV/EBITDA | -53.14 | 20.53 | Blueprint Medicines |
| Profit Margin (TTM) | -27.70% | 31.86% | Vertex |
| Operating Margin (TTM) | -27.50% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -47.71% | 22.77% | Vertex |
| Return on Assets (TTM) | -9.75% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-197.22M | $-978.00M | Blueprint Medicines |
| 1-Year Return | 12.60% | -16.36% | Blueprint Medicines |
| Price-to-Sales Ratio (TTM) | 14.89 | 9.06 | Vertex |
| Enterprise Value | $8.42B | $98.55B | Vertex |
| EV/Revenue Ratio | 14.97 | 8.63 | Vertex |
| Gross Profit Margin (TTM) | 98.12% | 86.25% | Blueprint Medicines |
| Revenue per Share (TTM) | $9 | $44 | Vertex |
| Earnings per Share (Diluted) | $-2.51 | $14.06 | Vertex |
| Beta (Stock Volatility) | 0.83 | 0.43 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Blueprint Medicines vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Blueprint Medicines | 0.00% | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% |
| Vertex | -0.10% | 1.92% | 1.94% | -12.30% | -15.10% | -0.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Blueprint Medicines | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
| Vertex | -16.36% | 37.41% | 84.75% | 252.43% | 1,018.23% | 1,674.89% |
News Based Sentiment: Blueprint Medicines vs Vertex
Blueprint Medicines
News sentiment data is not available for Blueprint Medicines at this time.
Vertex
News based Sentiment: MIXED
October presented a mixed bag for Vertex, with a major FDA approval and positive financial results offset by a failed clinical trial and increased operating expenses. The strategic pipeline advancements and strong financial position suggest continued growth potential, but investors should monitor the impact of the trial setback and expense increases.
Performance & Financial Health Analysis: Blueprint Medicines vs Vertex
| Metric | BPMC | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $8.37B | $103.40B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 5,799,940 | 1,835,420 |
| 90 Day Avg. Volume | 4,343,357 | 1,652,450 |
| Last Close | $129.46 | $402.90 |
| 52 Week Range | $73.04 - $129.65 | $362.50 - $519.88 |
| % from 52W High | -0.15% | -22.50% |
| All-Time High | $129.65 (Jul 16, 2025) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -0.15% | -22.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.56% | 0.12% |
| Quarterly Earnings Growth | -0.99% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | -0.28% | 0.32% |
| Operating Margin (TTM) | -0.28% | 0.39% |
| Return on Equity (TTM) | -0.48% | 0.23% |
| Debt to Equity (MRQ) | 208.50 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.30 | $67.02 |
| Cash per Share (MRQ) | $8.92 | $24.90 |
| Operating Cash Flow (TTM) | $-145,552,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-20,779,750 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Blueprint Medicines vs Vertex
| Metric | BPMC | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -120.99 | 28.68 |
| Forward P/E | -137.72 | 21.49 |
| PEG Ratio | -137.72 | -0.22 |
| Price to Sales (TTM) | 14.89 | 9.06 |
| Price to Book (MRQ) | 24.43 | 6.02 |
| Market Capitalization | ||
| Market Capitalization | $8.37B | $103.40B |
| Enterprise Value | $8.42B | $98.55B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 14.97 | 8.63 |
| Enterprise to EBITDA | -53.14 | 20.53 |
| Risk & Other Metrics | ||
| Beta | 0.83 | 0.43 |
| Book Value per Share (MRQ) | $5.30 | $67.02 |
Financial Statements Comparison: Blueprint Medicines vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BPMC | VRTX |
|---|---|---|
| Revenue/Sales | $149.41M | $2.96B |
| Cost of Goods Sold | $2.80M | $407.50M |
| Gross Profit | $146.61M | $2.56B |
| Research & Development | $91.89M | $978.40M |
| Operating Income (EBIT) | $-41.09M | $1.15B |
| EBITDA | $23.55M | $1.34B |
| Pre-Tax Income | $1.29M | $1.28B |
| Income Tax | $789,000 | $250.10M |
| Net Income (Profit) | $496,000 | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BPMC | VRTX |
|---|---|---|
| Cash & Equivalents | $122.25M | $4.67B |
| Total Current Assets | $702.07M | $10.01B |
| Total Current Liabilities | $250.58M | $3.78B |
| Long-Term Debt | $409.17M | $1.65B |
| Total Shareholders Equity | $342.13M | $16.50B |
| Retained Earnings | $-2.41B | $10.25B |
| Property, Plant & Equipment | $97.66M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BPMC | VRTX |
|---|---|---|
| Operating Cash Flow | $13.41M | $404.90M |
| Capital Expenditures | $-1.83M | $-40.70M |
| Free Cash Flow | $-56.31M | $778.20M |
| Debt Repayment | $-4.11M | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | BPMC | VRTX |
|---|---|---|
| Shares Short | 3.13M | 4.05M |
| Short Ratio | 0.62 | 2.83 |
| Short % of Float | 0.05% | 0.02% |
| Average Daily Volume (10 Day) | 5,799,940 | 1,835,420 |
| Average Daily Volume (90 Day) | 4,343,357 | 1,652,450 |
| Shares Outstanding | 63.71M | 256.94M |
| Float Shares | 60.00M | 255.58M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.09% | 0.98% |
Dividend Analysis & Yield Comparison: Blueprint Medicines vs Vertex
| Metric | BPMC | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |